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not related to vaspin-mediated changes in insulin sensitiv-
ity as determined by euglycemic-hyperinsulinemic clamp 
studies. Improved glucose metabolism could be mediated 
by increased insulin plasma concentrations 150 min after 
a glucose challenge in db/db mice, supporting the hypoth-
esis that vaspin may inhibit insulin degradation by hK7 in 
the circulation. In conclusion, we demonstrate the inhibi-
tory serpin nature and the first protease target of the adipose 
tissue-derived serpin vaspin, and our findings suggest hK7 
inhibition by vaspin as an underlying physiological mecha-
nism for its compensatory actions on obesity-induced insu-
lin resistance.
Keywords Vaspin · SerpinA12 · Kallikrein 7 · Crystal 
structure · Diabetes · Insulin
Introduction
Obesity represents a fast-growing health problem that is 
reaching epidemic proportions worldwide [1] and is associ-
ated with an increased risk of premature death [2]. Obesity 
significantly increases the risk of developing type 2 diabetes 
mellitus, hypertension, coronary heart disease, stroke and 
several types of cancer [3]. Understanding the molecular 
mechanisms linking adipose tissue to these obesity related 
pathologies is of enormous scientific and medical impor-
tance. Cells of adipose tissue produce and secrete a variety of 
cytokines and cytokine-like molecules, termed adipokines, 
which have effects on insulin sensitivity, glucose and lipid 
levels, satiety and appetite [4].
Previously, visceral adipose tissue-derived serpin 
(referred to as vaspin in this paper; serpinA12 according 
to the serpin nomenclature [5]) was identified as a putative 
member of the serine protease inhibitor family, which was 
Abstract The molecular target of the adipokine vaspin 
(visceral adipose tissue-derived serpin; serpinA12) and its 
mode of action are unknown. Here, we provide the vaspin 
crystal structure and identify human kallikrein 7 (hK7) as a 
first protease target of vaspin inhibited by classical serpin 
mechanism with high specificity in vitro. We detect vaspin–
hK7 complexes in human plasma and find co-expression 
of both proteins in murine pancreatic β-cells. We further 
demonstrate that hK7 cleaves human insulin in the A- and 
B-chain. Vaspin treatment of isolated pancreatic islets leads 
to increased insulin concentration in the media upon glu-
cose stimulation without influencing insulin secretion. 
By application of vaspin and generated inactive mutants, 
we find the significantly improved glucose tolerance in 
C57BL/6NTac and db/db mice treated with recombinant 
vaspin fully dependent on the vaspin serpin activity and 
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expressed in visceral adipose tissue of Otsuka Long-Evans 
Tokushima Fatty (OLETF) rats at the age when obesity 
and insulin plasma concentrations reach a peak [6]. Vaspin 
expression was shown to decrease with worsening of diabe-
tes and body weight loss, whereas vaspin serum levels could 
be normalized by insulin or pioglitazone treatment. Consist-
ent with that, we found increased vaspin mRNA expression 
in human adipose tissue associated with obesity, insulin 
resistance and type 2 diabetes [7].
Administration of vaspin to obese mice improves 
glucose tolerance, insulin sensitivity and altered gene 
expression of candidate genes for insulin resistance [6]. 
In addition, we could demonstrate that central vaspin 
administration leads to reduced food intake and has sus-
tained blood glucose-lowering effects in mice [8], and this 
has since been confirmed in rats [9]. We and others have 
recently reported that elevated vaspin serum concentra-
tions are associated with obesity and impaired insulin sen-
sitivity in humans [10, 11].
It has therefore been postulated that increased vaspin 
expression and secretion could represent a compensatory 
mechanism associated with obesity, severe insulin resist-
ance, and type 2 diabetes [6]. Althoughprotease inhibitor 
properties have been suggested as mechanism of vaspin 
action, until now a protease target of vaspin has not yet 
been identified. Here, we demonstrate the inhibitory ser-
pin nature of vaspin by identifying human kallikrein 7 
(hK7) as the first protease target of vaspin and confirm the 
vaspin–hK7 interaction in human plasma. We find human 
insulin as a substrate of hK7 and co-expression of vaspin 
and hK7 in pancreatic islets. We provide evidence that the 
serpin function of vaspin is essential for its physiologic 
effects and demonstrate that the anti-diabetic vaspin effects 
in vivo do not result from increased insulin sensitivity but 
are rather based on an insulin-stabilizing effect most likely 
by inhibiting hK7-mediated insulin degradation. Thus, 
our results give insight into the molecular mechanism of 
reported beneficial vaspin effects in obesity-related meta-
bolic dysfunction.
Materials and methods
Generation of 10×His–vaspin fusion protein
Expression of native human vaspin, cloned into the pET-
16b bacterial expression vector (10×histidin tag; Qiagen, 
Hilden, Germany), and variants vaspinT365R and vaspi-
nA369P in E. coli BL21(DE3)pLysRARE was induced by 
the addition of isopropyl β-thiogalactopyranoside (1 mM) to 
the growth medium. Bacterial extracts were prepared using 
standard methods, and the fusion protein was purified by 
immobilized metal ion affinity chromatography (NiNTA 
FastStart kit; Qiagen) (Supplementary Fig. S1A–D). Protein 
identity and purity were affirmed by SDS–PAGE, HPLC, 
Western blot and MALDI-TOF mass spectrometry. Acti-
Clean Etox affinity columns (Sterogene Bioseparations, 
Carlsbad, CA, USA) were used to remove potential endo-
toxin contaminations.
Crystallization and X-ray structure determination
Vaspin structure analysis was performed by crystallization 
and X-ray structure determination to 2.08 Ǻ data resolu-
tion. Prior to crystallization, the protein was subjected to 
a final gel filtration chromatography step (Superdex200 
16/60 column; GE Healthcare, München, Germany; elu-
tion buffer containing 10 mM Tris pH 7.2 and 150 mM 
NaCl). Peak fractions were pooled and concentrated to 
about 8.4 mg/ml. In a hanging-drop vapor diffusion setup 
at 292 K, 1 μl protein and 1 μl reservoir solution were 
mixed and equilibrated against the reservoir solution of 
0.5 ml containing 9 % (w/v) polyethylene glycol 4000, 
0.1 M (NH4)2SO4 and 0.1 M sodium citrate pH 5.1. Crys-
tals of up to 50 × 130 × 200 μm formed within 1–3 weeks 
(Supplementary Fig. S1E). The analyzed crystal was trans-
ferred stepwise to a buffer containing 20 % ethylene glycol 
in addition to the components in the crystallization buffer 
and frozen in liquid nitrogen. The diffraction data were 
integrated and scaled with the XDS [12] program pack-
age. The phase problem was solved by molecular replace-
ment (program PHASER [13]) using the sequence-identity 
based truncated coordinates (program CHAINSAW [14]; 
side chains of non-conserved amino acids were truncated to 
the Cβ position) of human α1-antitrypsin (PDB id 1QLP) as 
the search model. The asymmetric unit contains two vaspin 
molecules. After modeling, refinement and validation 
(CCP4 programs [15] including COOT [16], REFMAC5 
[17], BUSTER-TNT [18] and MolProbity [19]), the struc-
ture was deposited in the RCSB PDB as 4IF8. The final 
model comprises residues 37–366 and 378–414 of chain 
A and residues 35–277, 280–365 and 382–413 of chain 
B (full details in Table 1). Figure 1a was prepared using 
PyMOL (http://www.pymol.org).
Protease activity assays for hK4, hK5 and hK7
The activity assay for human recombinant hK4, hK5 and 
hK7 (all from R&D Systems, Minneapolis, MN, USA) were 
performed according to the manufacturers’ protocols using 
the recommended fluorogenic peptide substrates ES011 
(hK4, hK5) and ES002 (hK7) (all from R&D) with minor 
modifications. Recombinant hK4 and hK7 were activated 
by thermolysin (R&D Systems) prior to the activity assay 
according to the manufacturers’ protocol. The stoichiom-
etry for the reaction of recombinant vaspin with hK7 was 
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determined as described previously [20]. Briefly, to a fixed 
concentration of protease hK7 (19 nM) increasing concen-
trations of vaspin were added to give molar ratios of inhibi-
tor to protease of up to 5 in a final volume of 55 μl. After 
incubating for times sufficient to complete the reaction 
(>95 %), 25 μl of each reaction mixture was transferred to 
a 96-well plate and 75 μl of substrate solution (13.3 μM) 
were automatically injected into each well. The residual 
enzymatic activity was measured in duplicates from the 
initial linear rate of change of emission at 405 nm. The 
decrease in protease activity with increasing molar ratio of 
inhibitor/protease was fit by linear regression to obtain the 
stoichiometry of inhibition (SI) from the abscissa intercept. 
Association rate constant for the reaction of vaspin and hK7 
were measured under pseudo-first-order conditions by using 
a tenfold molar excess of vaspin. Plots of remaining hK7 
activity versus time demonstrated exponential loss of activ-
ity and the kass kinetic constant was determined based on the 
equations ln [E] = −kobs · t and kass = kobs/[I] by linear fit to 
a plot of ln activity versus time [20].
Analysis of vaspin–hK7 complex formation and in vitro 
digestion of native human insulin by hK7
For Western blot analysis, recombinant human vaspin and 
vaspin variants were incubated with or without hK7 at a 
molar ratio of 1:1 at RT. At indicated time point, SDS-
samples were taken and ~200 ng total protein per lane 
were separated by SDS–PAGE and analyzed after West-
ern blotting using primary antibodies for vaspin (Adipo-
gen, South Korea), His-Tag (Abcam) or hK7 (Uscn Life 
Science, Wuhan, China). To isolate vaspin–enzyme com-
plexes in human serum and plasma samples recombinant 
vaspin was added and allowed to form complexes and then 
isolated by affinity purification via its His-tag. Therefore, 
25 μg of recombinant vaspin was added to 500 μl serum 
or plasma and incubated for 90 min at RT without protease 
inhibitors and with or without immediate addition of 100 μl 
Ni–NTA bead slurry (Abcam). After 90 min, 100 μl of 
Ni–NTA bead slurry and protease inhibitor cocktail were 
added to those samples without Ni–NTA beads and they 
were were incubated overnight at 4 °C on a rotator. Serum 
and plasma samples without vaspin, but otherwise treated 
identically, served as control for the affinity pull-down. 
After incubation times, the Ni–NTA beads were washed 
three times using a buffer with low concentration of imida-
zole (TBS, 150 mM imidazole, pH 8) and affinity purified 
protein complexes were eluted using Lämmli buffer con-
taining 500 mM imidazole. Elution fractions were sepa-
rated by SDS–PAGE and analyzed by Western blot using 
above mentioned antibodies.
For MS analysis, recombinant human vaspin was incu-
bated with or without hK7 at a molar ratio of 5:1 for 24 h at 
RT to allow for vaspin–hK7 complex formation with respect 
to the observed complex stability in SDS–PAGE analysis. 
Reaction mixtures were desalted using ZipTip C18-filter 
tips (Millipore) and analyzed by MALDI-TOF MS and 
MSMS using LIFT mode on a Bruker Ultraflex III MALDI 
TOF/TOF mass spectrometer. Native insulin (Insuman 
Rapid; Sanofi-Aventis, Paris, France) was incubated at 
0.75 mg/ml with activated 0.02 mg/ml hK7 for 60 min at 
37 °C. HK7 activity was terminated by addition of 50 μM 
Pefabloc SC (Roche) and insulin fragments were reduced 
with 5 mM TCEP for 1 h at RT. Digests were analyzed by 
MALDI-TOF mass spectrometry and resulting peaks were 
further analyzed by MSMS mass spectrometry. Peak lists 
of MSMS spectra were searched against the SwissProt  
database using the Mascot search engine (Matrix Science, 
London, UK; http://www.matrixscience.com) in order to 
identify peptide fragments. For database searches, the fol-
lowing parameters were used—species: homo sapiens; 
digestion: none; monoisotopic masses; variable modifica-
tion: methionine residues oxidized; mass tolerance MS: 
100 ppm; mass tolerance MSMS: 0.5 Da.
Table 1  Details of data collection and refinement for vaspin crystal 
structure analyses
Space group C2
Unit cell, a (Å) 133.6
 b (Å) 152.1
 c (Å) 61.5
 β (°) 97.5




Last shell (Å) 2.13–2.08
Completeness (%) 99.9 (100)a
Unique reflections 72,713
Multiplicity 4.3 (4.3)a
Rsym (%) 5.1 (48.3)a
Rrim (%)c 5.7 (54.6)a
Average I/σ (I) 19.5 (3.4)a
Wilson B (Å2) 40.2
Mean B (Å2) 52.9
Number of residues and mean B value (Å2) in brackets
 Chain A 367 (38.5)
 Chain B 361 (68.4)
 Sulfate 2 (66.3)
 Water 224 (42.8)
Rwork/Rfree (%) 20.3/22.2
r.m.s.d. bonds/angles (Å, °) 0.01/1.08
All-atom contacts clashscore 5.25
Molprobity score 1.69
a  Values in parentheses refer to the highest resolution (last) shell
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Animals
All animal studies have been performed in accordance to the 
Guide for the Care and Use of Laboratory Animals (NIH 
Publication No. 85-23, revised 1996) and were approved 
by the local authorities of the state of Saxony, Germany, as 
recommended by the responsible local animal ethics review 
board.
Vaspin intraperitoneal (i.p.) treatment glucose tolerance 
test (GTT) and euglycemic-hyperinsulinemic clamp studies
Before i.p.- GTT and euglycemic-hyperinsulinemic clamp 
studies, mice were given two i.p. injections (2200 hours, and 
then at 0800 hours the following day before the procedure) of 
pyrogen-free saline or vaspin (1 mg/kg body weight). GTT 
was performed as described previously [21]. Euglycemic-
hyperinsulinemic clamp studies were performed on female 
db/db mice (BKS.Cg-m+/+Leprdb/BomTac; Taconic, Lille 
Skensved, Denmark) at the age of 16 weeks. After an over-
night fast (12 h), catheter implantation and hyperinsulinemic-
euglycemic clamps were performed as described previously 
[22]. In brief, the insulin clamp was conducted with a con-
tinuous infusion of human insulin at a rate of 60 mU/kg/min 
to lower plasma glucose levels within a physiological range 
(~5 mmol/l). Physiological blood glucose concentrations 
were maintained by adjusting infusion of a 20 % glucose 
solution. Steady state was ascertained when glucose meas-
urements were constant for 20 min at a fixed glucose infu-
sion rate and was achieved within 120–240 min. Steady 
state was maintained for 45 min and blood samples (10 μL) 
were taken at 0 and 5 min, and then at 10-min intervals after 
reaching steady state. All infusions were done using micro-
dialysis pumps (TSE Systems, Chesterfield, MO, USA).
Pancreas histology and immunofluorescence
Pancreatic islets were isolated from 12-week-old 
C57BL/6JRj mice (n = 3) which were bred and housed in 
the Animal Laboratories at the University of Leipzig, Ger-
many, under strict hygienic conditions. Mice were main-
tained at a 12-h light/dark cycle (0500/1700 hours) and had 
free access to food (V1536; Ssniff; Soest, Germany) and 
water. The pancreas was fixed with 4 % buffered formal-
dehyde, embedded in paraffin and cut in 7-μm-thick serial 
sections, which were either stained with hematoxylin–eosin 
(H&E) or immunostained for vaspin (Adipogen, South 
Korea) or hK7 (Uscn Life Science). As secondary antibod-
ies, HRP coupled anti-rat immunoglobulins (AbD Serotec, 
Oxford, UK) and Envision dual link system-HRP (Dako, 
Fig. 1  Crystal structure of vaspin. A stereo view of the better defined monomer A of the asymmetric unit. The residues of the reactive center 
loop (RCL) are illustrated as a dotted line and are flexible in the crystal structure (see also Supplementary Fig. S1F, G; Table 1)
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Glostrup, Denmark) were used as described previously [23]. 
Fluorescence immunohistology was performed on frozen 
pancreas sections of C57BL/6JRj mice. Slides were air-dried 
and fixed in ice-cold acetone for 10 min. Five slides, from 
various levels of the tissue, were stained with H&E for the 
evaluation of islets. Primary antibodies against vaspin (Adi-
pogen) and insulin (Santa Cruz Biotechnology, Heidelberg, 
Germany) were used. The fluorochrome conjugated second-
ary anti species antibodies, green (FITC-derived) and red 
(Cy3-derived), were from Zymed (Invitrogen, Karlsruhe, 
Germany). As negative controls, sections were incubated 
without primary antibodies to identify nonspecific binding 
(Supplementary Fig. S6B, C).
Islet isolation, Western blot and in vitro insulin secretion 
analysis
Islets of Langerhans were isolated from pooled pancreases 
of 12-week-old male C57BL/6JRj mice (n = 15). Pancreatic 
islets were prepared by fractionated collagenase digestion 
(Serva, Heidelberg, Germany) after separation from exo-
crine tissue and hand-picked under a stereomicroscope as 
previously described [23, 24]. For Western blot analysis, 
250 islets were lysed in 100 μl lysis buffer (20 mM Tris 
(pH 7.8), 150 mM NaCl, 0.5 % NP-40, protease inhibitor 
cocktail (Pierce) and 20 μg total protein were loaded per 
lane. For insulin secretion analysis, following islet isolation, 
groups of five islets were incubated with glucose concentra-
tions of 5.5 mmol/l under sterile condition in RPMI 1640 
medium supplemented with 10 % fetal calf serum, 20 mmol/l 
l-glutamine, 100 U/ml penicillin and 100 g/ml streptomy-
cin (all from Sigma-Aldrich, Munich, Germany) for 24 h at 
37 °C under a humidified gas atmosphere (5 % CO2:95 % 
O2). Islet function was tested for each single experiment by 
islet insulin content after incubation experiments using dif-
ferent glucose concentrations (5.5, 11.1, 22.2 mmol/l). For 
insulin release assays, 5 islets were statically incubated in 
Krebs–Ringer buffer and stimulated for 2.5 h at 37 °C with 
various glucose concentrations (5.5, 11.1, 22.2 mmol/l) 
with or without vaspin (1 μg/100 μl and 10 ng/ml medium). 
Supernatant was collected and assayed for insulin content 
by ELISA. Islets were then sonicated in acid–ethanol solu-
tion and solubilized over night at 4 °C before assaying total 
insulin content using Ultra Sensitive Mouse Insulin ELISA 
Kit (Crystal Chem, Downers Grove, IL, USA).
Statistical analyses
Data are given as mean ± standard errors of the mean 
(SEM) unless stated otherwise. Datasets were analyzed for 
statistical significance using a two-tailed unpaired Student’s 
t test, or differences were assessed by one-way ANOVA cor-
rected by Bonferroni–Holm using the Statistical Package for 
Social Science, v.14.0 (SPSS, Chicago, IL, USA). p values 
<0.05 were considered significant.
Results
Vaspin crystal structure
Based on sequence homology with α1-antitrypsin vaspin has 
been predicted to belong to the serpin protein family [6]. 
After expression, purification and crystallization of recom-
binant human vaspin (Supplementary Fig. S1A–E), X-ray 
structure determination confirmed the typical structural 
core domains of serpins consisting of three β-sheets and 
nine α-helices (Fig. 1). As expected, nearby regions match 
closely in a superposition onto related serpins (Supplemen-
tary Fig. S1F, G). The fold corresponds to that of free ser-
pins or serpins involved in a transient complex, i.e. the long 
central β-sheet consists of five strands. The reactive center 
loop (RCL) (extending from G364 to P381) is flexible in the 
vaspin structure. Details of data collection and refinement 
are listed in Table 1.
Vaspin inhibits hK7 via serpin mechanism
In an initial screening for a target protease, vaspin failed 
to inhibit serine proteases trypsin, elastase, urokinase, col-
lagenase, factor Xa and dipeptidyl peptidase [6]. Instead of 
screening a broad range of proteases, we decided to focus 
on the kallikrein (hK) family, since vaspin has been shown 
to co-localize with kallikrein 5 (hK5) in human skin [25]. 
hK4, hK5 and hK7 are closely related evolutionarily [26] 
and were therefore tested in an initial screening. Primary 
investigation of hK4, hK5 and hK7 inhibition by vaspin was 
performed by monitoring protease activity over a range of 
molar ratios of serpin to protease using adequate fluorogenic 
peptide substrates. While vaspin failed to inhibit proteolytic 
activity of hK4 and hK5 (Fig. 2a), hK7 activity was sig-
nificantly inhibited by vaspin in a time- and concentration-
dependent manner (Fig. 2a, b). We determined the SI for the 
inhibition of hK7 by vaspin by incubating increasing ratios 
of vaspin to hK7 until completion of the reaction (residual 
hK7 activity <95 %) and obtained an SI of 3.4 ± 0.03 (Sup-
plementary Fig. S2A). The association rate constant, kass, 
for the reaction of vaspin with hK7 was determined under 
pseudo-first order conditions as 7.3 ± 1.8 × 103 M−1 s−1 
(Supplementary Fig. S2B).
Members of the serpin family typically form SDS-sta-
ble complexes with target proteases. To investigate com-
plex formation and stability of the serpin–enzyme complex 
(SEC), we incubated hK7 and vaspin at a molar ratio of 
1/1.4. Consistent with the observed hK7 inhibition pro-
gress by vaspin, the proteins formed stable complexes with 
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Fig. 2  Identification of hK7 as protease target of vaspin. a Remain-
ing proteolytic activity of closest related kallikrein members hK5, 
hK4 and hK7 after incubation with indicated molar excess of recom-
binant vaspin (10 min at RT). b Time course of hK7 inhibition with 
or without tenfold excess of vaspin (for stoichiometry and association 
rate constant of inhibition see Supplementary Fig. S2). c SDS–PAGE 
analysis and silver staining demonstrating vaspin–hK7 complex for-
mation and stability over a period of 24 h (times presented in min-
utes). hK7 and vaspin (ratio of 1:1.4) or vaspin alone were incubated 
for the indicated time. d Immunodetection of vaspin, vaspin–hK7 
complex and cleaved vaspin using anti-HisTag or anti-vaspin anti-
body. e Affinity purified vaspin–hK7 complex from human serum 
and plasma as detected by Western blot using anti-vaspin and anti-
hK7 antibodies (lane 1/8 rec. vaspin control, lane 2/5 Ni–NTA bead 
control, lane 3/6 vaspin and Ni–NTA beads simultaneously, lane 4/7 
vaspin and Ni–NTA beads successively). f Non-inhibitory variants 
vaspinT365R and vaspinA369P fail to inhibit hK7 proteolytic activ-
ity (tenfold excess, 60 min at RT). g, h Non-inhibitory vaspin vari-
ants are unable to form serpin–hK7 complexes and serve as substrates 
only, as demonstrated for vaspinA369P by SDS–PAGE and Western 
blot analysis. Results are expressed as the percentages of the value in 
the absence of vaspin (a, b, f), each bar representing the mean ± SD 
(n = 2–5) (c–e, g, h). Data shown are representative of at least two 
independent experiments
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an apparent molecular weight of ~70 kDa as detected by 
silver staining of SDS–PAGE gels (Fig. 2c), anti-vaspin and 
anti-HisTag Western blot (Fig. 2d) and MALDI-TOF mass 
spectrometry (Supplementary Fig. S4B). The complexes 
were stable under reducing conditions. Complex formation 
was detectable after 5 min, reached a plateau after 60 min 
and remained level for at least 24 h without significant 
complex dissociation (Fig. 2c). In parallel, the decrease in 
intensity of the intact vaspin band (~47 kDa) and increase 
of a ~42 kDa band mainly results from cleavage after a 
tyrosine residue within the artificial His-tag sequence of 
recombinant vaspin and only to minor extent from complex 
dissociation (Fig. 2c) as revealed by Western blot analysis 
(Fig. 2d). The slightly lower migrating band of cleaved 
vaspin due to slowly ongoing serpin–protease deacylation 
is only faintly detectable using the anti-His-tag antibody, 
while the tag-cleaved vaspin is detected as a clear band 
when using an anti-vaspin antibody (Fig. 2d). Furthermore, 
an additional band representing the degraded complex is 
detectable in the silver-stained gel and Western blot analysis 
(Fig. 2c, d), which is not unusual given an increased pro-
teolytic susceptibility of the protease in complex with the 
serpin [27]. The control lanes of either vaspin or hK7 alone 
showed no additional bands to the native protein bands and 
neither hK4 nor hK5 were able to form complexes (unpub-
lished observation).
We have tried to isolate endogenous vaspin–hK7 com-
plexes from human serum and plasma, as well as lysates 
from isolated murine islets, but due to the low expression 
of both proteins in the samples and the potentially short 
half-life of the complex due to degradation or clearance, 
we were not able to detect endogenous vaspin–hK7 com-
plexes by Western blotting. After addition of recombinant 
vaspin to human serum and plasma samples, complex for-
mation by vaspin and very likely hK7 in human plasma 
could be detected as identified by Western blotting after 
affinity pull-down via the His-tag (Fig. 2e). The hK7 anti-
body primarily detects a band migrating below the full 
complex, most probably due to degradation of the exposed 
protein in the complex (protease inhibitors were not added 
to the reaction mixture, since protease activity is needed 
for complex formation) or better epitope accessibility 
for the antibody (Fig. 2e). We have observed a compara-
ble complex degradation product for the in vitro formed 
complex of vaspin and hK7 as a band with a similar molec-
ular weight in the Western blots shown in Fig. 2d. Interest-
ingly, complex formation was only marginally observed in 
human serum, suggesting that circulating hK7 is lost dur-
ing blood clotting.
X-ray structures of SECs demonstrate that after initial 
cleavage of the RCL remaining residues beginning at the 
P15 glycine, following the standard nomenclature [28], are 
inserted into the β-sheet A as a new β-strand [27, 29]. The 
P15 glycine is located in a tight turn between anti parallel 
β-strands and is highly conserved within the serpin family 
(Supplementary Fig. S1G) [30], most likely because torsion 
angles in this conformation are only allowable for the least 
restricted amino acid glycine in the Ramachandran plot. It 
has been shown that the serpin inhibitory mechanism is crit-
ically dependent on the length of the RCL [31] and is fur-
thermore structurally based on conserved small side-chain 
amino acids within the hinge region of inhibitory serpins 
(Table 2). This also applies to vaspin, as the mutation of ala-
nine 369 to proline (vaspinA369P) within the vaspin hinge 
region converts vaspin from inhibitor of hK7 to substrate 
(Fig. 2f–h). Analogous results have been shown for other 
serpins, such as antithrombin and antitrypsin [32, 33]. The 
variant vaspinA369P fails to inhibit hK7 activity (Fig. 2f) 
and the mutation prevents complex formation with the pro-
tease (Fig. 2f, g). Furthermore, inhibitory serpins feature 
a non-charged amino acid at position P14 in contrast to a 
charged amino acid at this position within non-inhibitory 
serpins [34, 35]. The charged residue at P14 has been dem-
onstrated to significantly hinder RCL insertion into the cen-
tral β-sheet [36]. The exchange of P14 threonine to arginine 
(vaspinT365R) resulted in a non-inhibitory vaspin variant 
(Fig. 2f), serving as hK7 substrate with no detectable com-
plex formation (Supplementary Fig. S3).
Table 2  Reactive center loop 
(RCL) sequences for inhibitory 
human serpins and generated 




SerpinA1 Antitrypsin GTEAAGAMFLEAIPM– –SIPP
SerpinA1variant Pittsburgh GTEAAGAMFLEAIPR– –SIPP
SerpinA4 Kallistatin GTEAAAATTFAIKFF– –SAQT
SerpinA12 Vaspin GTEGAAGTGAQTLPM– –ETPL
SerpinC1 Antithrombin GSEAAASTAVVIAGR– –SLNP
SerpinE1 PAI–I GTVASSSTAVIVSAR– –MAPE
SerpinA12 variants VaspinA369P GTEGAPGTGAQTLPM– –ETPL
VaspinT365R GREGAAGTGAQTLPM– –ETPL
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Comparison of the RCL sequences of vaspin and other 
prominent serpins suggested methionine 378 as P1 residue 
(Table 2; Supplementary Fig. S4A), though tyrosine is the 
preferred P1 residue [37]. Indeed, we could confirm methio-
nine 378 as P1 residue for hK7 in vaspin by mass spectrom-
etry (Supplementary Fig. S4B, C).
Thus, hK7 represents the first target protease of vaspin, 
demonstrating functional relevance of vaspin as an inhibi-
tory serpin.
hK7 cleaves human insulin within A and B chain
Interestingly, a study on the substrate specificity of recom-
binant hK7 used the oxidized form of the bovine insulin B 
chain as a model substrate, revealing main cleavage sites at 
tyrosine 16 and tyrosine 26 [38]. Here, we confirm these 
cleavage sites for human insulin under native conditions 
(Supplementary Fig. S5A). In vitro cleavage of insulin by 
hK7 was analyzed by MALDI-TOF mass spectrometry 
(Supplementary Fig. S5B) and peak identities of insulin 
fragments were confirmed by MALDI-TOF–MSMS. We 
could further identify a cleavage site at tyrosine 14 in the 
insulin A chain, which has been previously unknown (Sup-
plementary Fig. S5A). A cleavage site after cysteine 7 in the 
B chain was only found under conditions of prior insulin 
reduction (unpublished observation). Accordingly, human 
insulin serves as a substrate of hK7.
Vaspin and hK7 are expressed in pancreatic islets
mRNA of 8 out of the 15 kallikrein family members is 
expressed in pancreatic tissue [37]. hK7 expression has pre-
viously been reported to be restricted to the (exocrine) pan-
creas [39, 40]. Immunohistochemical analysis of isolated 
murine pancreatic islets suggests that vaspin as well as hK7 
are expressed in different islet cell types (Fig. 3a, b). West-
ern blot analysis of isolated pancreatic islets from female 
and male C57BL/6JRj mice corroborate these observa-
tions with detectable protein expression of hK7 and vaspin 
(Fig. 3c; Supplementary Fig. S6A for male littermates) 
extending previous findings of vaspin mRNA expression 
in human pancreas [41]. Furthermore, fluorescence immu-
nochemistry indicates that vaspin might co-localize with 
insulin in pancreatic β-cells (Fig. 3d). Along these lines, we 
have analyzed pancreatic hK7 localization in parallel with 
insulin or glucagon (Fig. 3e, f). Co-localization of hK7 with 
insulin is substantially less clear, and hK7 seems unlikely 
to co-localize with glucagon in pancreatic α-cells (Fig. 3f). 
Specificity of the antibodies was confirmed using controls 
without primary antibodies (Supplementary Fig. S6B, C). 
Taken together, these data demonstrate co-expression of 
vaspin and hK7 in pancreatic islets and suggest co-localiza-
tion of vaspin and insulin in β-cells.
Vaspin effects on isolated murine pancreatic islets
Based on these findings, we tested the hypothesis that 
vaspin protects insulin from hK7-dependent degradation 
after secretion from the β-cell. Thus, we treated isolated 
pancreatic islets from C57BL/6JRj mice at different glucose 
concentrations with recombinant vaspin (10 μg/ml) and 
measured insulin concentration in the medium and islet 
insulin content. At a glucose concentration of 5.5 mmol/l, 
insulin concentrations in the medium were significantly 
increased in vaspin-treated islets, whereas islet insulin 
content was not altered compared to control islets (Fig. 4a, 
b). At higher glucose concentrations (11 and 22 mmol/l), 
vaspin treatment resulted in an even more pronounced, up 
to fourfold higher insulin concentration in islet superna-
tants compared to untreated control islets [Fig. 4a; Supple-
mentary Fig. S7A for absolute values (ng/islet/h)]. Experi-
ments using a lower vaspin concentration (10 ng/ml) gave 
comparable results (Supplementary Fig. S7B). Meanwhile, 
C-peptide levels in the supernatants and islet C-peptide con-
tent were not different between vaspin-treated and control 
islets (Fig. 4c, d) indicating that increased insulin accumu-
lation in the medium is due to reduced insulin degradation. 
Taken together, these observations support the hypothesis 
that vaspin may protect insulin from local degradation and 
degradation in the circulation by islet-derived hK7.
Improved glucose tolerance by vaspin is dependent on its 
serpin activity and increased insulin levels
Recombinant vaspin treatment of diet-induced obese mice 
has been previously demonstrated to improve glucose toler-
ance [6]. In addition, we have previously shown that vaspin 
treatment is associated with sustained glucose-lowering 
effects in db/db mice [8]. Here, we extend these findings by 
showing improved glucose tolerance after vaspin adminis-
tration in healthy C57BL/6NTac and in leptin receptor-defi-
cient db/db mice (Fig. 5a, b). To investigate, whether serine 
protease activity is required for vaspin effects on glucose 
metabolism, we treated db/db mice with native and the vari-
ant vaspinA369P, which lacks serine protease activity. We 
find that non-inhibitory vaspinA369P fails to improve glu-
cose tolerance in i.p. GTT in db/db mice (Fig. 5c), demon-
strating that improved glucose metabolism parameters after 
vaspin treatment are critically dependent on vaspin serpin 
activity.
To dissect the suggested role of vaspin as an endogenous 
insulin sensitizer [6] from its potential role as inhibitor of 
insulin degradation by hK7, we performed euglycemic-
hyperinsulinemic clamp studies in db/db mice. Interest-
ingly, glucose infusion rates during the last 45 min of the 
clamp were indistinguishable between vaspin and saline 
(control) treated mice (Fig. 5d), suggesting that changes in 
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Fig. 3  hK7 co-expression with 
vaspin in pancreatic islets. a, 
b Immunostaining of vaspin 
and hK7 in pancreatic islets of 
C57BL/6JRj mice. c Western 
blot analysis of vaspin and hK7 
protein expression in lysates 
of isolated islets of female 
C57BL/6JRj mice with cor-
responding recombinant control 
proteins (for male mice, see also 
Supplementary Fig. S6A).  
d Vaspin and insulin, e hK7 and 
insulin, and f hK7 and glucagon 
staining in pancreatic islets 
of C57BL/6JRj mice. Double 
staining of insulin and vaspin 
by fluorescence immunohistol-
ogy (merge, right) suggests 
co-localization of both proteins 
within insulin producing β-cells 
[d insulin (Cy3-channel, red), 
vaspin (FITC-channel, green); 
e, f insulin (FITC-channel, 
green), hK7 (Cy3-channel, red), 
nuclei (DAPI-channel, blue) 
from left to right]
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insulin sensitivity upon vaspin treatment do not represent the 
mechanism underlying improved glucose tolerance. In sub-
sequent experiments, we found significantly increased insu-
lin serum concentrations (Fig. 5e) in vaspin-treated db/db 
mice compared to saline-treated controls 150 min after a 
glucose challenge (2 mg/kg body weight). Despite higher 
post-glucose challenge insulin concentrations in vaspin-
treated mice, circulating C-peptide levels were not differ-
ent in vaspin- and saline-treated mice (Fig. 5f). A tendency 
for a lower C-peptide to insulin ratio further suggests that 
insulin is disproportionally higher than C-peptide (Fig. 5g), 
supporting the hypothesis that vaspin may inhibit insulin 
degradation in the circulation.
Discussion
Vaspin was identified as an adipokine with insulin-sensitiz-
ing effects, which is predominantly secreted from visceral 
adipose tissue in a rat model of type 2 diabetes [6] and has 
been shown to significantly reduce blood glucose concen-
trations in various mouse models [6, 8]. Therefore, vaspin 
may represent a novel treatment tool for diabetes interven-
tion strategies.
Here, we provide novel mechanistic and structural insight 
into previously reported improvement of glucose metabo-
lism after vaspin administration to rodent models of obesity 
and diabetes [6, 8]. To this point, the serpin family affiliation 
of vaspin has been based on sequence homology data [6]. 
We therefore recombinantly expressed human vaspin and 
determined the X-ray structure after crystallization of the 
protein confirming the typical structural core domains of ser-
pins consisting of three β-sheets and nine α-helices. Since a 
broad range of common serine proteases have already been 
screened for vaspin inhibition [6], we focused on the human 
kallikrein family previously unrecognized in this context. 
Circulating plasma levels of tissue kallikrein have been 
recently shown to be significantly higher in patients with 
type 2 diabetes compared to individuals with normal glu-
cose metabolism [42]. In addition, hK5 has been reported 
to be co-localized with vaspin in human skin [25], and a 
majority of hKs are expressed in the pancreas at least on 
the mRNA level [37]. Notably, hK7 substrate specificity has 
been investigated using bovine insulin B chain as substrate 
[38]. Consequently, we initially screened the closest related 
members, hK4, hK5 and hK7, for inhibition by vaspin. We 
found specific and serpin-mechanism-based inhibition of 
hK7 activity with kinetics of the inhibition reaction sup-
porting a physiological role of the vaspin–hK7 system. 
We could furthermore isolate vaspin–hK7 complexes from 
human plasma samples by affinity pull-down after addition 
of recombinant vaspin. Thus, our results demonstrate that 
vaspin is a functional serpin inhibiting the serine protease 
hK7.
Fig. 4  Vaspin effects on 
isolated murine islets. a Islets 
culture experiments after 2.5 h 
incubation with increasing 
glucose concentrations in the 
medium show significantly 
higher insulin medium  
concentrations at all glucose 
concentration for vaspin  
(10 μg/ml) treated islets [see 
also Supplementary Fig. S7A 
(absolute values) and Fig. 
S7B (vaspin treatment using 
10 ng/ml)]. b Insulin content 
of treated and untreated islets 
(#p < 0.05; ##p < 0.01 between 
different glucose concentra-
tions within treatment groups; 
*p < 0.05 for vaspin vs. control 
islets). c, d Relative C-peptide 
concentrations in the medium 
and relative C-peptide islet 
content at increasing glucose 
concentrations
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hK7 is best known for its role in skin desquamation [43, 
44], and there is growing evidence linking hK7 overexpres-
sion to endocrine-related malignancies, such as ovarian, 
breast and testicular cancer [45–47]. Interestingly, the role 
of hK7 in skin desquamation and recent data on vaspin and 
psoriasis might point to additional roles for the vaspin–hK7 
system in obesity-associated skin disease such as psoriasis 
[43, 44, 48].
However, the function of hK7 in other tissues or in 
metabolic diseases is far less understood. Interestingly, the 
bovine insulin B chain has been used as model substrate in 
an early study on substrate specificity of recombinant hK7 
[38]. Based on these data, we hypothesize that inhibition of 
hK7 by vaspin may prevent hK7-mediated insulin degrada-
tion both in the circulation, as suggested by the detection 
of vaspin–hK7 complexes in human plasma, and probably 
already beginning after secretion at the level of pancreatic 
islets. Formation of a vaspin–hK7 complex could thereby 
contribute to delayed insulin degradation in the circula-
tion and stabilize circulating insulin concentrations, sub-
sequently leading to improved insulin mediated glucose 
uptake.
Indeed, we provide in vitro data that human insulin rep-
resents a substrate of hK7 with cleavage sites in the A and 
B chain. Interestingly, hK7 cleavage sites of insulin are the 
same (Tyr14—A chain and Tyr16—B chain) or immedi-
ately next to (Tyr26 vs. Phe24 and Phe25 within B chain) 
cleavage sites of the major insulin-degrading enzyme (IDE) 
[49], suggesting that hK7 recognizes the three dimensional 
structure of insulin away from the insulin receptor binding 
site and thus might also be able to cleave receptor-bound 
insulin.
Moreover, vaspin and hK7 are co-expressed in pancreatic 
islets isolated from C57BL/6JRj mice and vaspin is co-
expressed with insulin in murine β-cells, supporting a physi-
ological role of the vaspin–hK7 interaction. Furthermore, 
Fig. 5  Glucose-lowering effects of vaspin in mouse models depend 
on serpin activity and are not based on increased insulin sensitiv-
ity but increased insulin levels without affecting insulin secretion. 
a, b Glucose tolerance during an i.p. GTT is improved after i.p. 
vaspin treatment (1 mg/kg) in C57BL/6NTac and db/db mice. c Non-
inhibitory vaspinA369P fails to improve glucose tolerance in i.p. 
GTT after i.p. administration (1 mg/kg) in db/db mice. d Euglycemic-
hyperinsulinemic clamp of female db/db mice after vaspin (2 mg/kg) 
or saline treatment with serum glucose concentrations (upper panel) 
and glucose infusion rate (lower panel) during last 45 min clamp. 
e–g Vaspin effects on serum insulin and C-peptide levels as well as 
C-peptide/insulin ratio in db/db mice 150 min after a glucose chal-
lenge (1 mg/kg vaspin; 2 mg/kg glucose) (*p < 0.05, **p < 0.01)
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these data suggest that the glucose-lowering effects of 
vaspin might already begin at the level of pancreatic islets. 
Indeed, we measured significantly increased insulin con-
centrations in supernatants of isolated pancreatic islets upon 
vaspin treatment under all glucose concentrations tested. 
Comparable C-peptide concentrations in the supernatants as 
well as islet insulin and C-peptide contents between vaspin-
treated and control islets very likely exclude an effect of 
vaspin on glucose-stimulated insulin secretion.
In vivo, vaspin treatment improved glucose tolerance in 
healthy C57BL/6NTac mice as well as in db/db mice. Impor-
tantly, GTTs comparing native and non-inhibitory vaspin 
variants demonstrate that serpin activity is essential for the 
glucose-lowering effects of vaspin, as the substrate-only 
variant vaspinA369P failed to improve glucose tolerance 
during i.p. GTT in db/db mice. Vaspin has been previously 
postulated to improve glucose tolerance by increasing insu-
lin sensitivity [6]. Using hyperinsulinemic-euglycemic 
clamp studies, we did not find an effect of vaspin admin-
istration on insulin sensitivity in db/db mice. However, in 
line with our in vitro findings that vaspin increases insulin 
medium concentrations secreted from isolated islets, a glu-
cose challenge in vaspin-treated db/db mice was associated 
with significantly increased serum insulin levels 150 min 
after glucose injection. The increase of serum insulin was 
not due to enhanced insulin secretion, since C-peptide levels 
were indistinguishable between vaspin- and saline-treated 
mice. Moreover, C-peptide to insulin ratio is twofold lower 
in vaspin-treated mice compared to control littermates. 
These data further support the hypothesis that vaspin does 
not increase insulin secretion or sensitivity, but stabilizes 
insulin plasma concentrations dependent on its serpin activ-
ity, most likely by inhibiting the insulin degrading protease 
hK7.
The study establishing a first valid hK7 ELISA found 
serum concentrations of human serum hK7 of 2.9 ± 0.9 
ng/ml for male and 2.3 ± 0.7 ng/ml for females, with range 
from 1.5 to 5 ng/ml [50]. Mean serum vaspin concentration 
have been reported as ~1 ng/ml [10, 11, 51, 52] and serum 
vaspin ranged from 0.01 to 6.74 ng/ml. Clinical relevance 
for comparable protease–protease inhibitor serum concen-
trations has been described in patients with pancreatic can-
cer, i.e. serum concentrations of the proteases such as trypsin 
or elastase are in an equimolar range with the corresponding 
serpins (α1-antichymotrypsin, α1-antitrypsin) [53]. On the 
other hand, for the relationship between the serpin PAI-1 
and its target protease tPA, ~3- to 5-fold higher serum con-
centrations have been found for the protease inhibitor com-
pared to the protease [54].
The determined rate constants for the interaction of 
vaspin and hK7 together with higher hK7 concentrations 
in the circulation compared to vaspin may limit the physi-
ologic relevance of this system. However, given the range of 
hK7 and vaspin expression, it is very likely that there exist 
at least subgroups of the population which have equimolar 
concentrations of vaspin and hK7. Furthermore, an excess 
of the protease may represent the healthy, physiologic situ-
ation. However, the serpin–protease ratio may change in the 
course of a disease. For vaspin, we and others have reported 
that elevated vaspin serum concentrations are associated 
with obesity and impaired insulin sensitivity in humans [10, 
11]. But, so far, influences of obesity or related metabolic 
diseases on the expression and serum concentration of hK7 
are unknown. Furthermore, it has been shown that vaspin 
expression follows a circadian rhythm, with expression 
peaks preceding postprandial insulin concentration peaks 
[55]. In this study, the authors concluded that the reciprocal 
relationship between serum vaspin and insulin may negate 
the importance of vaspin as a physiological insulin sensi-
tizer. As we could show, vaspin does not improve insulin 
sensitivity. But a pre-insulin expression peak of vaspin could 
acutely change the vaspin–hK7 ratio in favor of a relevant 
serpin–enzyme interaction and thus positively influence 
insulin action by providing protection from degradation. We 
can therefore conclude that, under physiologic conditions, 
the relevance of the vaspin–hK7 interaction may be limited, 
but the vaspin–hK7 ratio may change acutely after food 
ingestion before glucose-induced insulin levels peak or, on 
the other hand, under chronic conditions of hyperglycemia 
or other metabolic alterations under which the vaspin–hK7 
interaction may become significantly relevant. It is impor-
tant to note that we can not exclude that the beneficial meta-
bolic effects of vaspin treatment occur via vaspin influenc-
ing further or different proteolytic cascades that impact on 
cell function and insulin levels.
Small compound inhibitors of hK7 would be an adequate 
tool to address these questions. Recently, three isocoumarin 
small compound inhibitors for hK7 and hK5 have been 
reported [56]. However, natural and synthetic isocoumarin 
compounds have been reported to be rather broad serine 
protease inhibitors [57]. In line with these findings, the iso-
coumarin compounds reported by Teixeira et al. [56] are not 
selective by inhibiting both kallikreins tested, hK5 and hK7, 
and thus are not suitable. In addition, hK7 itself has several 
complex cellular effects including regulation of α5/β1 integ-
rin expression [58].
Noteworthy, the major IDE, a Zn2+ requiring metallo-
proteinase [59] can, due to its nature, be excluded as not 
being inhibited by vaspin. However, we did not system-
atically test whether vaspin has direct effects on insulin-
degrading enzyme. Since insulin clearance is dependent on 
binding to its receptor and subsequent internalization, we 
cannot exclude that vaspin has an effect on insulin binding 
or internalization. Noteworthy, interference of vaspin with 
normal insulin binding and degradation could also explain 
the metabolic effects of vaspin. Therefore, further studies 
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are necessary to test the hypotheses that vaspin has direct 
effects on IDE and that vaspin may interfere with insulin 
receptor binding and subsequent internalization.
A major site of insulin degradation is the liver, but also 
muscle and kidney, with a majority of the insulin degrada-
tion occurring intracellularly, dependent on preceding insu-
lin receptor-mediated internalization and clearance from 
circulation (reviewed in [49]). Taking our findings of hK7 
inhibition by vaspin, insulin cleavage by hK7 and serpin 
activity-dependent vaspin effects on glucose levels in vivo, 
our data indicate that additional degradation of insulin may 
be mediated by hK7. hK7-dependent degradation of insulin 
could be inhibited by vaspin, a process which may occur 
both at the level of pancreatic islets and in the circulation. 
Further studies are required to assess the quantitative con-
tribution of insulin degradation in the circulation by hK7 
to the net degradation of insulin. In addition, receptors for 
SECs such as the α1-antitrypsin–elastase complex have 
been reported [60] and shown to activate signal transduc-
tion pathways for increased serpin gene expression and to 
mediate SEC clearance from the circulation [61]. Further 
investigation is necessaryto identify a possible SEC receptor 
for the vaspin–hK7 complex and to investigate downstream 
signaling events potentially supporting already reported 
vaspin effects or triggering as yet unknown actions.
In summary, our data suggest that a major mechanism for 
previously reported glucose lowering effects of vaspin is to 
increase the half-life of insulin rather than improving insu-
lin sensitivity by functioning as an inhibitory serpin for the 
protease hK7. These findings suggest that the vaspin–hK7 
system as a potential novel target for anti-diabetic treatment 
strategies.
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